Goodman/AnGes MG
This article was originally published in The Gray Sheet
Executive Summary
License grants Japanese vascular interventional device firm Goodman exclusive rights to drug developer AnGes MG's NF-kappa B decoy patents for use in development of a drug coating for company's Duraflex stent and a biodegradable stent. NF-kappa B decoy "restrains the disorder among endothelial cells induced by cytokines, monocytes or macrophage invasion," Goodman explains in a release...